The project and its context
The Ministry of Health presented in Rome on October 12, 2026, during the event “Influenza Vaccination – From Information to Dialogue,” an official conversational agent called VITA, developed as part of the activities of the Directorate General for Communication. The meeting was attended by Undersecretary of State for Health Marcello Gemmato and the leaders of Italy's health sector. According to the source, the goal is to move from one-way communication to direct dialogue with citizens, capable of gathering questions and clarifying doubts about vaccination.
The project was born against a backdrop of declining vaccination coverage. According to the data reported, the share of over-65s vaccinated against influenza fell from 65.3% in the 2020-2021 season to 52.5% in 2024-2025, more than twenty points below the minimum target of 75% set by health authorities. Regional differences are marked: ranging from 65.8% in Umbria to 35.7% in Sardinia.
The reasons for hesitancy and the role of AI
The causes of reluctance are multifaceted. The cited ISTAT surveys indicate that 29.5% of elderly people with underlying conditions do not believe they are at risk, while 17.5% fear adverse reactions. These reasons are compounded by vaccine fatigue after the pandemic, the lack of an explicit recommendation from a doctor, and misinformation on digital channels.
Professor Silvio Tafuri, full professor of Hygiene at the University of Bari Aldo Moro and scientific co-coordinator of the project's Steering Committee, explained that a recent Demopolis survey finds that more than 40% of Italians use generative artificial intelligence systems to seek health information, with a rising trend. Hence the Ministry's decision to test a conversational channel based on institutional sources.
What remains to be verified
The material does not specify the agent's operational results or the timeline for rollout. It does not indicate whether VITA is already available to the public, on which platforms it operates, or how its effectiveness is measured. It therefore remains to be verified in the field whether the tool will be able to affect coverage—an objective the project sets for itself but one that the cited data do not yet allow for assessment.
A central element highlighted by the source is the relationship with doctors and scientific validation, cited as pillars of the project, but without details on how they will be implemented. The news should therefore be read as the announcement of a strategy in its launch phase, not as an intervention whose effects have already been evaluated.
